The Headline Numbers
SURMOUNT-1 trial results (tirzepatide 15 mg for weight management):
- Average weight loss: 22.5% of body weight at 72 weeks
- For a 250-pound patient, that’s approximately 56 pounds
- Over one-third of patients lost 25% or more of body weight
- More than half lost 20% or more
These results made tirzepatide the most effective non-surgical weight loss treatment ever studied in randomized controlled trials. The weight loss exceeds what most patients achieve with lifestyle changes alone (typically 3–5%) and approaches results seen with bariatric surgery.
Important: Mounjaro is FDA-approved for type 2 diabetes only — it is not FDA-approved for weight loss. The weight management version of tirzepatide is Zepbound (FDA-approved November 2023). Both contain the same molecule — the weight loss potential is the same regardless of brand name. At PEAK, we prescribe Zepbound for weight loss patients. The SURMOUNT trial data below studied tirzepatide for weight management (as Zepbound), not for diabetes.
SURMOUNT Trial Results in Detail
The SURMOUNT clinical trial program studied tirzepatide specifically for weight management in adults with obesity or overweight with weight-related conditions:
| Study | Population | Duration | 15 mg Result | Key Finding |
|---|---|---|---|---|
| SURMOUNT-1 | Obesity/overweight without T2D | 72 weeks | -22.5% | Historic weight loss for non-surgical treatment |
| SURMOUNT-2 | Obesity/overweight WITH T2D | 72 weeks | -14.7% | Significant even with diabetes (harder to lose weight) |
| SURMOUNT-3 | After intensive lifestyle intervention | 72 weeks | -26.6% total | Additional loss beyond lifestyle changes |
| SURMOUNT-4 | Maintenance after initial loss | 88 weeks | Maintained loss | Continued treatment prevents regain |
Results by Dose
| Dose | Average Weight Loss (SURMOUNT-1) | % Losing >20% |
|---|---|---|
| 5 mg | -16.0% | 27% |
| 10 mg | -21.4% | 46% |
| 15 mg | -22.5% | 57% |
| Placebo | -2.4% | <1% |
The dose-response relationship is clear but notably, even the 5 mg dose produced clinically meaningful weight loss (16%)—far exceeding what lifestyle modifications alone typically achieve.
Weight Loss Timeline
Understanding the typical trajectory helps set realistic expectations:
| Timeframe | Expected Progress | What’s Happening |
|---|---|---|
| Weeks 1–4 | 1–3% body weight | Initiation dose (2.5 mg); appetite reduction begins |
| Months 2–3 | 5–8% | Therapeutic doses reached; significant appetite suppression |
| Months 4–6 | 10–15% | Approaching maximum dose; steady weight loss |
| Months 6–9 | 15–20% | Near-maximum efficacy; rate may slow |
| Months 9–18 | 20–25% | Approaching plateau; body reaching new equilibrium |
| Month 18+ | Maintenance | Weight stabilizes; continued medication maintains loss |
Weight loss on tirzepatide is not linear. The fastest loss occurs during months 3–9 as doses escalate. By month 12–18, loss slows as your body reaches a new metabolic equilibrium—this isn't the medication failing; it's working to maintain your new weight.
Factors That Affect Individual Results
Clinical trial averages don’t tell the whole story. Several factors influence where you’ll fall on the spectrum:
- Starting weight: Patients with higher starting BMI tend to lose more absolute weight but similar percentages
- Diabetes status: Patients with type 2 diabetes typically lose less weight than those without—SURMOUNT-2 showed 14.7% vs. 22.5% in SURMOUNT-1
- Dose achieved: Higher maintenance doses produce greater weight loss. Not all patients tolerate or need the maximum 15 mg
- Diet and exercise: Patients who combine tirzepatide with structured nutrition (especially high protein) and exercise achieve better body composition outcomes
- Medication adherence: Consistent weekly injections without missed doses maximize results
- Genetics: Emerging research suggests genetic variation in GLP-1 and GIP receptor expression affects individual response
- Other medications: Some medications (steroids, certain antidepressants, insulin) can partially counteract weight loss
Tirzepatide vs. Semaglutide Results
While no head-to-head trial has directly compared maximum-dose tirzepatide to maximum-dose semaglutide for weight loss, cross-trial comparisons suggest:
| Metric | Tirzepatide (SURMOUNT-1) | Semaglutide (STEP 1) |
|---|---|---|
| Average weight loss | -22.5% (15 mg) | -14.9% (2.4 mg) |
| % losing >10% | ~90% | ~69% |
| % losing >20% | ~57% | ~32% |
| Trial duration | 72 weeks | 68 weeks |
The SURPASS-2 trial (for diabetes) directly compared tirzepatide and semaglutide, with tirzepatide demonstrating superior weight loss and blood sugar control at all dose levels.
The additional GIP receptor activation in tirzepatide appears to provide a meaningful additive effect beyond GLP-1 stimulation alone, though individual response varies.
Setting Realistic Expectations
While the clinical data is impressive, context matters:
- You may not reach the average. Individual results range widely—some patients lose 30%+ while others respond more modestly
- Non-responders exist. Approximately 10–15% of patients don’t achieve clinically meaningful weight loss (5%+). This doesn’t mean failure—it means this particular medication isn’t the right fit
- Weight loss requires continued treatment. SURMOUNT-4 showed that stopping tirzepatide leads to weight regain, similar to what’s seen with semaglutide
- Body composition matters more than scale weight. Tirzepatide combined with exercise and adequate protein preserves lean muscle, improving metabolic health beyond what the scale shows
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
